CCR researchers show selumetinib shrinks tumors in children with NF1

Findings from a phase 2 clinical trial show that the drug selumetinib improves outcomes for children with the genetic disorder neurofibromatosis type 1 (NF1). In the trial, selumetinib shrank the inoperable tumors that develop with NF1 called plexiform neurofibromas, and children experienced reduced pain, improved function, and better overall quality of life after receiving the treatment. This trial was led by Brigitte Widemann, M.D., Chief of the Pediatric Oncology Branch (POB), and Andrea M. Gross, M.D., Assistant Research Physician in POB, and the results were published March 18, 2020, in the New England Journal of Medicine. Read more...

CCR researchers show selumetinib shrinks tumors in children with NF1
Martha Zeiger

Martha Zeiger elected President of the American Thyroid Association

Dec 11, 2019

Martha Zeiger, M.D., Head of the Surgical Oncology Program, was recently elected President of the American Thyroid Association (ATA) and received the association’s 2019 Lewis E. Braverman Distinguished Award. The award is presented annually to an individual who demonstrates excellence and passion for mentoring fellows, students and junior faculty, has a long history of productive thyroid research and is devoted to the ATA. Read more...

Lasker Foundation logo

Newest Lasker Scholars Nirali Shah and David Takeda featured in Intramural Research Program blog

Dec 11, 2019

Nirali Shah, M.D., M.H.Sc., Investigator in the Pediatric Oncology Branch, and David Takeda, M.D., Ph.D., Investigator in the Laboratory of Genitourinary Cancer Pathogenesis, are two of the five physician-scientists selected as the 2019 class of Lasker Clinical Research Scholars. In a recent Intramural Research Program blog, they discuss their research and how the resources at NCI and NIH have helped support their goals.  Read more...


POSTPONED: RNA Imaging and Intracellular Dynamics Workshop

Dec 9, 2019

RNA biology has emerged as one of the most influential areas in modern biology and biomedicine. The NCI is home to a wide spectrum of work in RNA biology ranging from elucidating RNA biogenesis and structure, identifying functions for various classes of RNAs, establishing the role of RNA in disease and exploring RNA-based and RNA-targeted therapies.

This workshop will focus on how basic steps in RNA metabolism are carried out and are integrated into a complex intracellular environment. It aims to bring together experts in the field to describe recent advances in methodologies used to understand subcellular RNA distribution, organization and function, discuss the impact they have had on current models and identify key areas of future development. Read more...

Cancer Health Disparities info

POSTPONED: 3rd NCI Symposium on Cancer Health Disparities

Dec 9, 2019

Cancer health disparities affect millions of people across the United States. Disparities in cancer burden are evident by geography, race/ethnicity, genetic ancestry, immigrant status, culture, gender, sexual orientation (LGBTQ+) and socioeconomic class, among other factors. The 3rd NCI Symposium on Cancer Health Disparities will present recent advances in our understanding of the causes of cancer health disparities in rural populations and among Native Americans, focus on the roles of financial toxicity and the tumor immune profile in causing outcome disparities and discuss evidence-based strategies to reduce these disparities, including novel approaches to prevention and precision medicine. Read more...

Jonathan Hernandez

Jonathan Hernandez named one of Washington, D.C.’s best doctors

Dec 6, 2019

Jonathan Hernandez, M.D., Investigator in the Surgical Oncology Program, has been selected as one of Washington, D.C.’s 2019 top doctors by The Washingtonian. Top Doctors are selected by nearly 13,000 doctors in D.C., Maryland and Virginia who name a colleague they would recommend in a variety of specialties. Read more...

HIV infecting healthy cell

Unlocking the key to HIV persistence

Dec 2, 2019

Even though antiretroviral therapies have allowed many people to live long lives, ridding the body of HIV completely has been an elusive goal ever since the discovery in the 1980s that HIV causes AIDS. New research from the Center for Cancer Research shows that proviral DNA sequences and their integration at specific sites could provide clues for researchers developing drugs to eradicate AIDS.  Read more...

T cells

Clinical trial evaluates T-cell therapy for advanced mesothelin-expressing cancers

Nov 26, 2019

Some cancer cells express a higher-than-normal amount of mesothelin, which makes them more likely to multiply and spread to other parts of the body. Raffit Hassan, M.D., of the Thoracic and GI Malignancies Branch, is leading a trial that tests T-cell immunotherapy for patients with cancer of the lung and its lining, ovarian cancer and bile duct cancer that express high levels of mesothelin. Read more...

Mitochondrial shape in pancreatic cancer

Computational analysis leads to potential new drug combination for pancreatic cancer

Nov 20, 2019

A computer analysis has been able to predict that low levels of asparagine, an amino acid required for protein synthesis, combined with the shutdown of a stress response pathway can lead to reductions in the fitness of a tumor. These combined findings could potentially lead to new combination therapies to treat aggressive tumors, such as those found in pancreatic cancers. Read more...

Prostate imaging

Clinical trial will test radiotracer imaging for high-risk localized prostate cancer

Nov 19, 2019

Many men with prostate cancer are diagnosed at an early stage of the disease when the cancer is confined to the prostate. However, about 20 percent are diagnosed with high-risk disease, which tends to spread, or metastasize, to other parts of the body. William Dahut, M.D., Senior Investigator in the Genitourinary Malignancies Branch, is leading a study using positron emission tomography/computed tomography (PET/CT) with radioactive material to try and identify places in the body where prostate cancer has spread. Read more...

Fusing a ring system onto an existing chromophore

New video: Discovering new far-red fluorescent probes

Nov 18, 2019

Fluorescent probes are workhorse molecules used by biologists to illuminate the inner workings of cancer cells. By lighting up cell components of interest, researchers can then observe cells in action through high-powered microscopes. This new video explains a novel class of far-red fluorescent probes synthesized by Martin Schnermann, Ph.D., Senior Investigator in CCR’s Chemical Biology Laboratory, and his team. Read more...